Plain-English translation of NCT07309094 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether semaglutide, a weekly injection medication that helps lower blood sugar and reduce weight, can improve the health of your kidneys and heart. The study focuses on how this medication affects unhealthy fat tissue in the body, which plays a major role in kidney disease, diabetes, and heart problems. Researchers want to understand whether the medication can reduce harmful fat deposits and protect your organs.
Many people with kidney disease also struggle with diabetes, high blood pressure, and obesity—and these conditions are all connected through unhealthy fat tissue that triggers inflammation and organ damage. This medication has shown promise in treating diabetes and weight, but doctors want to specifically study whether it can improve kidney function and reduce the harmful effects of abnormal fat tissue in patients with kidney disease.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either semaglutide injections (given weekly under the skin, starting at a low dose and gradually increasing), or another kidney-protective medication, or standard care depending on which group you're assigned to. You will have clinic visits where doctors will measure your body composition, take blood samples to check your kidney function and inflammation markers, and possibly perform imaging scans to examine your fat tissue. The study involves 250 participants total and will help researchers understand how well the medication works to protect your kidneys and improve your overall cardiometabolic health.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Spain